Maxim Group set a $15.00 price objective on Anavex Life Sciences Corp. (NASDAQ:AVXL) in a report issued on Monday morning. The firm currently has a buy rating on the biotechnology company’s stock.

Several other research firms have also commented on AVXL. Zacks Investment Research upgraded shares of Anavex Life Sciences Corp. from a hold rating to a buy rating and set a $4.75 price target for the company in a report on Monday, August 28th. Noble Financial restated a buy rating and issued a $15.00 price target on shares of Anavex Life Sciences Corp. in a report on Friday, September 29th. Finally, ValuEngine lowered shares of Anavex Life Sciences Corp. from a hold rating to a sell rating in a report on Thursday, September 28th.

Anavex Life Sciences Corp. (NASDAQ:AVXL) traded up 1.68% during trading on Monday, reaching $4.23. The company’s stock had a trading volume of 198,009 shares. Anavex Life Sciences Corp. has a one year low of $2.76 and a one year high of $6.64. The company has a 50-day moving average of $4.33 and a 200 day moving average of $4.33. The firm’s market cap is $178.39 million.

Anavex Life Sciences Corp. (NASDAQ:AVXL) last announced its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.09) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.09). Analysts expect that Anavex Life Sciences Corp. will post ($0.37) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Anavex Life Sciences Corp. (AVXL) Given a $15.00 Price Target at Maxim Group” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/10/31/anavex-life-sciences-corp-avxl-given-a-15-00-price-target-at-maxim-group.html.

Several hedge funds and other institutional investors have recently bought and sold shares of AVXL. Vanguard Group Inc. raised its stake in shares of Anavex Life Sciences Corp. by 13.1% during the 1st quarter. Vanguard Group Inc. now owns 1,485,681 shares of the biotechnology company’s stock worth $8,528,000 after acquiring an additional 171,577 shares in the last quarter. State Street Corp grew its position in Anavex Life Sciences Corp. by 15.2% during the 2nd quarter. State Street Corp now owns 603,326 shares of the biotechnology company’s stock worth $3,210,000 after purchasing an additional 79,516 shares during the last quarter. Northern Trust Corp grew its position in Anavex Life Sciences Corp. by 16.0% during the 2nd quarter. Northern Trust Corp now owns 429,073 shares of the biotechnology company’s stock worth $2,282,000 after purchasing an additional 59,069 shares during the last quarter. Geode Capital Management LLC grew its position in Anavex Life Sciences Corp. by 16.8% during the 1st quarter. Geode Capital Management LLC now owns 276,974 shares of the biotechnology company’s stock worth $1,589,000 after purchasing an additional 39,934 shares during the last quarter. Finally, Marshall Wace North America L.P. purchased a new stake in Anavex Life Sciences Corp. during the 2nd quarter worth approximately $176,000. Hedge funds and other institutional investors own 24.22% of the company’s stock.

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.

Receive News & Stock Ratings for Anavex Life Sciences Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences Corp. and related stocks with our FREE daily email newsletter.